ACHL vs. PLUR, CRTX, INAB, BCLI, TARA, INKT, SRZN, NKGN, ZIVO, and ESLA
Should you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Pluri (PLUR), Cortexyme (CRTX), IN8bio (INAB), Brainstorm Cell Therapeutics (BCLI), Protara Therapeutics (TARA), MiNK Therapeutics (INKT), Surrozen (SRZN), NKGen Biotech (NKGN), ZIVO Bioscience (ZIVO), and Estrella Immunopharma (ESLA). These companies are all part of the "medical" sector.
Achilles Therapeutics (NASDAQ:ACHL) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.
Achilles Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -6,708.40%. Achilles Therapeutics' return on equity of -42.95% beat Pluri's return on equity.
Pluri has higher revenue and earnings than Achilles Therapeutics. Pluri is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Achilles Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Achilles Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 325.49%. Given Achilles Therapeutics' higher probable upside, equities research analysts clearly believe Achilles Therapeutics is more favorable than Pluri.
56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by insiders. Comparatively, 24.3% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Achilles Therapeutics received 17 more outperform votes than Pluri when rated by MarketBeat users.
In the previous week, Achilles Therapeutics had 6 more articles in the media than Pluri. MarketBeat recorded 7 mentions for Achilles Therapeutics and 1 mentions for Pluri. Achilles Therapeutics' average media sentiment score of 1.20 beat Pluri's score of 0.33 indicating that Achilles Therapeutics is being referred to more favorably in the media.
Summary
Achilles Therapeutics beats Pluri on 11 of the 15 factors compared between the two stocks.
Get Achilles Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achilles Therapeutics Competitors List
Related Companies and Tools
